A new study suggests GLP-1 medications, such as semaglutide, were associated with better overall outcomes in people with type ...

New discussion around Parkinson’s treatment is putting dopamine agonists under the spotlight, with clinicians balancing motor ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as Ozempic or Wegovy, have revolutionized type 2 diabetes and ...

Our easy-to-read fact sheet provides clinicians with an overview of the mechanism of GLP-1 agonists. Our easy-to-read fact sheets provide clinicians with reliable information to share with patients ...

Originally developed to treat diabetes, a class of drugs known as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are now stepping into the spotlight as weight loss drugs. A recent umbrella ...

High-profile coverage of the off-label use of Ozempic, a GLP-1 agonist, for weight loss, has meant that the type 2 diabetes drug has received a lot of bad press. As more studies into the long-term ...

Beta-agonists (β-agonists) are the only drugs that directly open narrowed airways and make it easier to breathe for millions of people with asthma, a chronic respiratory disease. These inhaled ...

The cGAS-STING signaling pathway has emerged as a major focus in cancer immunotherapy because it stimulates interferon production and enhances antitumor immune responses. However, despite strong ...

As a sensor of cellular energy status, the AMP-activated protein kinase (AMPK) is believed to act in opposition to the metabolic phenotypes favored by proliferating tumor cells. Consequently, ...

GLP-1 receptor agonist drugs, used for the treatment of diabetes, and more recently, weight loss, are associated with a significantly lower long term risk of knee replacement surgery as a result ...

GLP-1 receptor agonists may lower the likelihood of psychiatric treatment intensification in patients with type 2 diabetes and depression.